Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
35.22
+1.47 (4.36%)
Feb 21, 2025, 4:00 PM EST - Market closed
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Agios Pharmaceuticals stock have an average target of 56.33, with a low estimate of 46 and a high estimate of 75. The average target predicts an increase of 59.94% from the current stock price of 35.22.
Analyst Consensus: Buy
* Price targets were last updated on Dec 10, 2024.
Analyst Ratings
The average analyst rating for Agios Pharmaceuticals stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 18, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $55 → $57 | Buy | Maintains | $55 → $57 | +61.84% | Dec 10, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $53 → $75 | Buy | Maintains | $53 → $75 | +112.95% | Dec 9, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $55 | Buy | Reiterates | $55 | +56.16% | Nov 1, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $51 → $53 | Buy | Maintains | $51 → $53 | +50.48% | Nov 1, 2024 |
Financial Forecast
Revenue This Year
97.17M
from 36.50M
Increased by 166.22%
Revenue Next Year
192.74M
from 97.17M
Increased by 98.36%
EPS This Year
-6.63
from 11.64
EPS Next Year
-5.54
from -6.63
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 281.1M | 250.3M | 592.9M | ||
| Avg | 97.2M | 192.7M | 408.2M | ||
| Low | 51.0M | 143.6M | 217.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 670.2% | 157.6% | 207.6% | ||
| Avg | 166.2% | 98.4% | 111.8% | ||
| Low | 39.6% | 47.8% | 12.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.38 | -3.97 | -0.63 | ||
| Avg | -6.63 | -5.54 | -2.19 | ||
| Low | -7.65 | -7.24 | -4.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.